Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Mills

Showing results (1111-1120 of 1,298) with videos related to

Pageof 130
Sort By:
Science Translational Medicine|June 2, 2017
Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in <i>RAS</i> mutant cancersChaoyang Sun, Yong Fang, Jun Yin, et al.
Nature Biotechnology|May 13, 2020
Multiplex digital spatial profiling of proteins and RNA in fixed tissueChristopher R Merritt, Giang T Ong, Sarah E Church, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2015
Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination TherapiesClemens Krepler, Min Xiao, Katrin Sproesser, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 19, 2010
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancerSherene Loi, Benjamin Haibe-Kains, Samira Majjaj, et al.
Cancer Research|October 10, 2014
Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanomaY N Vashisht Gopal, Helen Rizos, Guo Chen, et al.
Cell Reports|November 1, 2018
Comprehensive Molecular Characterization of the Hippo Signaling Pathway in CancerYumeng Wang, Xiaoyan Xu, Dejan Maglic, et al.
Journal of the National Cancer Institute|April 12, 2015
A decision support framework for genomically informed investigational cancer therapyFunda Meric-Bernstam, Amber Johnson, Vijaykumar Holla, et al.
JCI Insight|September 21, 2021
Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancerMehdi Bouhaddou, Rex H Lee, Hua Li, et al.
Cell Reports. Medicine|December 21, 2022
Spatial heterogeneity of infiltrating T cells in high-grade serous ovarian cancer revealed by multi-omics analysisBin Yang, Xiong Li, Wei Zhang, et al.
Nature Communications|April 1, 2021
Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug responseDimitra Georgopoulou, Maurizio Callari, Oscar M Rueda, et al.
Pageof 130

Showing results (1111-1120 of 1,298) with videos related to

Sort By:
Pageof 130
Science Translational Medicine|June 2, 2017
Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in <i>RAS</i> mutant cancersChaoyang Sun, Yong Fang, Jun Yin, et al.
Nature Biotechnology|May 13, 2020
Multiplex digital spatial profiling of proteins and RNA in fixed tissueChristopher R Merritt, Giang T Ong, Sarah E Church, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2015
Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination TherapiesClemens Krepler, Min Xiao, Katrin Sproesser, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 19, 2010
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancerSherene Loi, Benjamin Haibe-Kains, Samira Majjaj, et al.
Cancer Research|October 10, 2014
Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanomaY N Vashisht Gopal, Helen Rizos, Guo Chen, et al.
Cell Reports|November 1, 2018
Comprehensive Molecular Characterization of the Hippo Signaling Pathway in CancerYumeng Wang, Xiaoyan Xu, Dejan Maglic, et al.
Journal of the National Cancer Institute|April 12, 2015
A decision support framework for genomically informed investigational cancer therapyFunda Meric-Bernstam, Amber Johnson, Vijaykumar Holla, et al.
JCI Insight|September 21, 2021
Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancerMehdi Bouhaddou, Rex H Lee, Hua Li, et al.
Cell Reports. Medicine|December 21, 2022
Spatial heterogeneity of infiltrating T cells in high-grade serous ovarian cancer revealed by multi-omics analysisBin Yang, Xiong Li, Wei Zhang, et al.
Nature Communications|April 1, 2021
Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug responseDimitra Georgopoulou, Maurizio Callari, Oscar M Rueda, et al.
Pageof 130